IBio is Still Sitting in the Starting Gates of the Vaccine Race: Sep 18: iBio Is a Wishful Thinkers Coronavirus Vaccine Bet: Sep 9: Why iBio Stock Is Soaring Today: Sep 9: iBio +14% on advancement of IBIO-201, COVID-19 LicKM-subunit vaccine: Sep 9: iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201: Sep 9 2 days ago · iBio, Inc. (IBIO), a biotech innovator and biologics contract manufacturing organization, today announced the closing of its underwritten public offering of approximately 29.7 million shares of its common stock for gross proceeds of $35.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by iBio. IBIO -- Is Its Stock Price A Worthy Investment? Learn More. Stocknews.com IBIO Stock Summary The capital turnover (annual revenue relative to shareholder's equity) for IBIO is 0.03 -- better than just 10.55% of US stocks. With a price/sales ratio of 190.41, iBio Inc has a higher such ratio than 98.12% of stocks in our set.